Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelmnews2022-01-12T01:22:10+00:00January 12th, 2022|The New York Times|
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decisionnews2021-12-31T21:39:22+00:00December 31st, 2021|The New York Times|
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstaclesnews2021-12-21T02:08:14+00:00December 21st, 2021|The New York Times|
Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drugnews2021-11-22T16:00:09+00:00November 22nd, 2021|The New York Times|
Biogen’s Alzheimer’s drug is unlikely to win E.U. approval.news2021-11-18T04:32:41+00:00November 18th, 2021|The New York Times|
Sales of Biogen’s Alzheimer’s Drug Fall Short of Expectationsnews2021-10-20T20:06:11+00:00October 20th, 2021|The New York Times|
House Committees Demand F.D.A. Records on Alzheimer’s Drug Approvalnews2021-09-02T17:20:46+00:00September 2nd, 2021|The New York Times|
Weekly Health Quiz: Covid, Aloe and Heartburnnews2021-08-26T09:00:02+00:00August 26th, 2021|The New York Times|
Biogen’s Aduhelm Sales Total $2 Million in Second Quarternews2021-07-22T21:10:02+00:00July 22nd, 2021|The New York Times|
